Jia wei zuo jin wan
Food supplement declared in France, declaration No 2024-1-613, decision dated 13 January 2024
Jia wei zuo jin wan (Laboratoire Calebasse) is a food supplement declared in France. Status: déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité). 3 points in its composition require a check (prohibited substance, dose or novel food). 3 rules of use apply to its ingredients (limits and warnings).
- Brand
- Laboratoire Calebasse
- Food business operator placing the product on the market
- Calebasse
- Status
- Déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité)
- Form
- Gélule
- Daily dose
- 3 g
- Directions for use
- 3g soit 6 gélules
- Not recommended for (according to the manufacturer)
- Adolescents (moins de 18 ans), Femmes allaitantes, Enfants (moins de 12 ans), Enfants en bas âge (1 à 3 ans), Femmes enceintes, Hypertension, Nourrissons (moins de 1 an), Problèmes cardiaques, Problèmes de foie, Sous anticoagulants, Sous antidiabétiques, Sous traitement médicamenteux, Utilisation prolongée, Enfants (de moins de 6 ans), Enfants (de moins de 10 ans)
- Objectives stated by the manufacturer (these are not authorised claims)
- Digestion
Declaration 312393, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 23 October 2026.
Regulatory points
- À vérifier
Paeonia spp. (zie ook lijst 3/voir aussi liste 3): dangerous plant prohibited in food in Belgium (list 1). The entire genus Paeonia is listed. List 3 also covers Paeonia lactiflora Pall., parts: fleur, racine, graine. L'étiquetage doit comporter l’avertissement suivant : Ne pas utiliser en cas de grossesse. Check the plant part used, the preparation, the conditions and the product notification.
Source: Belgium, Royal Decree of 31 August 2021, plant lists (annex replaced on 30 January 2024), arrêté royal du 31 août 2021, annexe remplacée le 30 janvier 2024, liste 1, page PDF 78 ; liste 3, pages PDF 206.
- À vérifier
Scutellaria baicalensis Georgi (zie ook lijst 3/voir aussi liste 3): dangerous plant prohibited in food in Belgium (list 1). L’utilisation de la racine provenant de cette plante est autorisée dans les denrées alimentaires. List 3 also covers Scutellaria baicalensis Georgi, parts: feuille, racine. Check the plant part used, the preparation, the conditions and the product notification.
Source: Belgium, Royal Decree of 31 August 2021, plant lists (annex replaced on 30 January 2024), arrêté royal du 31 août 2021, annexe remplacée le 30 janvier 2024, liste 1, page PDF 82 ; liste 3, pages PDF 251.
- À vérifier
Scutellaria spp.: dangerous plant prohibited in food in Belgium (list 1). The entire genus Scutellaria is listed. List 3 also covers Scutellaria baicalensis Georgi, parts: feuille, racine. Check the plant part used, the preparation, the conditions and the product notification.
Source: Belgium, Royal Decree of 31 August 2021, plant lists (annex replaced on 30 January 2024), arrêté royal du 31 août 2021, annexe remplacée le 30 janvier 2024, liste 1, page PDF 83 ; liste 3, pages PDF 251.
- Conditions légales
Citrus aurantium L.: La quantité ingérée de p-synéphrine doit être inférieure à 20 mg par dose journalière recommandée. L'étiquetage doit comporter un avertissement déconseillant l'emploi aux enfants, aux femmes enceintes ou allaitantes et en cas de traitement anti-hypertenseur. La caféine et les sources de caféine ne sont pas autorisées dans les compléments alimentaires contenant Citrus aurantium L.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
- Conditions légales
Cyperus rotundus L.: L'étiquetage doit comporter un avertissement déconseillant l'emploi aux femmes enceintes et allaitantes.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
- Conditions légales
Glycyrrhiza uralensis Fisch.: La portion journalière recommandée ne doit pas conduire à une ingestion d'acide glycyrrhizinique supérieure à 100 mg. L'étiquetage doit comporter un avertissement avec la teneur suivante: "Ne pas utiliser pendant plus de 6 semaines sans avis médical." L'étiquetage doit comporter un avertissement déconseillant l'emploi chez les enfants.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Citrus reticulata Blanco | Péricarpe | Extrait sec aqueux | 0.6 g |
| Citrus aurantium L. | Péricarpe | Extrait sec aqueux | 0.57 g |
| Paeonia lactiflora Pall. | Racine | Extrait sec aqueux | 0.57 g |
| Angelica sinensis (Oliv.) Diels | Racine | Extrait sec aqueux | 0.23 g |
| Bupleurum chinense DC. | Racine | Extrait sec aqueux | 0.23 g |
| Cyperus rotundus L. | Rhizome | Extrait sec aqueux | 0.23 g |
| Glycyrrhiza uralensis Fisch. | Racine | Extrait sec aqueux | 0.23 g |
| Scutellaria baicalensis Georgi | Racine | Extrait sec aqueux | 0.23 g |
| Coptis teeta Wall. | Rhizome | Extrait sec aqueux | 0.11 g |
Additives
E1204
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Label warnings
Déconseillé aux personnes sous traitement antidiabétique, aux personnes présentant de troubles hépatiques ou cardiaque, sous traitement contre l’hypertension ou sous traitement anticoagulants, consultez votre médecin ou pharmacien. Ne pas utiliser plus de 6 semaines sans avis médical. Déconseillé en cas d'usage prolongé. Déconseillé en cas d’hypertension artérielle, de pathologies cardiaques ou rénales, d’insuffisance hépatique, et de tout trouble de l’équilibre hydro-électrolytique. Prendre conseil auprès d'un professionnel de la santé si vous suivez un traitement médicamenteux.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Angelica sinensis (Oliv.) Diels
Read the warning, when it applies and the studies cited
DONG QUAI - ANGELICA SINENSIS
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding (NS 2021).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Ask a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you are taking any medications including blood thinners, birth control pills or hormone therapy (NS 2021; Brinker 2010; WHO 2002).
3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have serious or major conditions, any type of acute infection, deficiency or excess (HC 2022).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
When using this product avoid exposure to the sun (NS 2021; Thorne 2004).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Contraindications
Do not use if you are pregnant (NS 2021; WHO 2002).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Do not use if you have diarrhea, hemorrhagic diseases or heavy periods (NS 2021, Bensky et al. 2004; Chen and Chen 2004; WHO 2002).
4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Known adverse reactions
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen, or if new symptoms develop such as breast pain or any changes in menstrual cycles (Brinker 2010; Schumacher et al. 2007; Thorne 2004; Russell et al. 2002).
4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
- Glycyrrhiza uralensis Fisch.
Read the warning, when it applies and the studies cited
DEGLYCYRRHIZINATED LICORICE Buccal
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Health Canada monograph dated 31 October 2025
Deglycyrrhizinated Licorice Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Health Canada monograph dated 31 January 2025
LICORICE
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding (Gardner and McGuffin 2013).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Condition of application: Cough relief.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if cough worsens or persists (for) more than 1 week (EMA 2012).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Condition of application: Gastritis relief.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Contraindications
Condition of application: All products.
Do not use if you are pregnant (EMA 2012).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Do not use if you have hypokalemia, high blood pressure, or a kidney, liver or cardiovascular disorder (EMA 2012; Brinker 2010; ESCOP 2003; Bradley 1992).
4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Do not use if you are taking heart medications, corticosteroids, stimulant laxatives, or other health products that may contribute electrolyte imbalance (Brinker 2010; ESCOP 2003; Hoffmann 2003; Blumenthal et al. 2000).
4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Other declarations with the same name
In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.
- Jia wei zuo jin wan Calebasse verte, declared in 2022 : different composition: 1 ingredient(s) added, 1 missing
- Jia wei zuo jin wan Calebasse verte, declared in 2022, earlier declaration, replaced by the 2024 declaration : different composition: 1 ingredient(s) added, 0 missing
- Jia wei zuo jin wan Calebasse verte, declared in 2019, earlier declaration, replaced by the 2024 declaration : different composition: 2 ingredient(s) added, 1 missing
Brand : Laboratoire Calebasse
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.